Lista de obras - Julia Gee - Dominio Público Uruguay

A cautionary note regarding the application of Ki-67 antibodies to paraffin-embedded breast cancers

artículo científico publicado en 1995

A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer.

artículo científico publicado en 2013

A review of the biological and clinical characteristics of luminal-like oestrogen receptor-positive breast cancer.

artículo científico

ADAM metalloproteases and EGFR signalling

artículo científico publicado en 2003

Acquired resistance to oestrogen deprivation: role for growth factor signalling kinases/oestrogen receptor cross-talk revealed in new MCF-7X model.

artículo científico publicado en 2005

Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer

artículo científico publicado en 2004

Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells

artículo científico publicado en 2008

BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer

artículo científico publicado en 2013

BRCA1 expression levels predict distant metastasis of sporadic breast cancers

artículo científico publicado en 1999

Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth.

artículo científico publicado en 2005

Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype

artículo científico publicado en 2007

Cell proliferation in prostatic carcinoma: comparative analysis of Ki-67, MIB-1 and PCNA

scientific article published on 01 March 1995

Change in expression of ER, bcl-2 and MIB1 on primary tamoxifen and relation to response in ER positive breast cancer

artículo científico publicado en 2001

Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment.

artículo científico publicado en 2005

Corrigendum to “ONCOPOOL – A European database for 16,944 cases of breast cancer” [European Journal of Cancer 46 (2009) 56–71]

scholarly article published in European Journal of Cancer

Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells.

artículo científico publicado en 2012

Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications.

artículo científico publicado en 2006

Development of strategies for the use of anti-growth factor treatments.

artículo científico publicado en 2005

Differential Expression of Oestrogen Regulated Genes in Breast Cancer

article

Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study

artículo científico publicado en 2012

ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer.

artículo científico publicado en 2012

Effects of fulvestrant 250mg in premenopausal women with oestrogen receptor-positive primary breast cancer

scientific article published on 24 October 2006

Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes

article

Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.

artículo científico publicado en 2005

Endocrine response and resistance in breast cancer: a role for the transcription factor Fos.

artículo científico publicado en 1999

Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex).

artículo científico publicado en 2001

Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy.

artículo científico publicado en 1994

Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.

artículo científico publicado en 2005

Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer

scientific article published on 02 May 2022

Estrogen deprivation in breast cancer. Clinical, experimental, and biological aspects

artículo científico publicado en 1990

Evaluation of the current knowledge limitations in breast cancer research: a gap analysis

artículo científico publicado en 2008

Expanding the therapeutic repertoire of epidermal growth factor receptor blockade: radiosensitization

artículo científico publicado en 2003

Extreme growth factor signalling can promote oestrogen receptor-alpha loss: therapeutic implications in breast cancer

artículo científico publicado en 2004

Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance.

artículo científico publicado en 2008

Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1

artículo científico publicado en 2011

Gamma linolenic acid with tamoxifen as primary therapy in breast cancer

scientific article published on 01 March 2000

Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.

artículo científico publicado en 2013

Growth factor receptor interplay and resistance in cancer

artículo científico publicado en 2006

Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer.

artículo científico publicado en 2005

Growth factor signalling in endocrine and anti-growth factor resistant breast cancer.

artículo científico publicado en 2007

Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance.

artículo científico publicado en 2009

Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells

artículo científico publicado en 2007

Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy

scientific article published on 01 December 1994

Immunocytochemical localization of fos protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy

artículo científico publicado en 1995

Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro

artículo científico publicado en 2014

Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells.

artículo científico publicado en 2004

Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy.

artículo científico publicado en 2006

Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells.

artículo científico publicado en 2006

Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance.

artículo científico publicado en 2007

Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor.

artículo científico publicado en 2005

Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells

artículo científico publicado en 2004

Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes

artículo científico publicado en 2007

Investigating the mechanism of enhanced cytotoxicity of HPMA copolymer-Dox-AGM in breast cancer cells

artículo científico publicado en 2006

Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer.

artículo científico publicado en 2001

Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination

artículo científico publicado en 2004

ONCOPOOL - a European database for 16,944 cases of breast cancer.

artículo científico publicado en 2010

Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.

artículo científico publicado en 2003

Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.

artículo científico publicado en 2012

Overview of tyrosine kinase inhibitors in clinical breast cancer.

artículo científico publicado en 2005

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

artículo científico publicado en 2002

Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.

artículo científico publicado en 2008

Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer

artículo científico publicado en 2001

Phosphorylation of ERα at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERα phosphorylation in breast cancer progression

scientific article published on 01 September 2006

Presence and possible significance of immunocytochemically demonstrable metallothionein over-expression in primary invasive ductal carcinoma of the breast.

artículo científico publicado en 1993

Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer

artículo científico publicado en 2007

Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets

artículo científico publicado en 2014

Role of endoplasmic reticulum stress induction by the plant toxin, persin, in overcoming resistance to the apoptotic effects of tamoxifen in human breast cancer cells.

scientific article published on 31 October 2013

Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer

artículo científico publicado en 1996

Steroid hormone receptors and their clinical significance in cancer.

artículo científico publicado en 1995

TENB2, a proteoglycan identified in prostate cancer that is associated with disease progression and androgen independence

artículo científico publicado en 2001

The Biology of Antihormone Failure in Breast Cancer ⬇️

artículo científico publicado el 1 de enero de 2003

The effects of gefitinib in tamoxifen-resistant and hormone-insensitive breast cancer: a phase II study.

artículo científico publicado en 2010

The immunohistochemical expression of desmoplakin and its role in vivo in the progression and metastasis of breast cancer

scientific article published on 01 June 1999

Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen.

artículo científico publicado en 2009

Understanding endocrine resistance: the critical need for sequential samples from clinical breast cancer and novel in vitro models

artículo científico publicado en 2005

Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies.

artículo científico publicado en 2005

Lista de obras de Julia Gee

A cautionary note regarding the application of Ki-67 antibodies to paraffin-embedded breast cancers

A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer.

A review of the biological and clinical characteristics of luminal-like oestrogen receptor-positive breast cancer.

ADAM metalloproteases and EGFR signalling

Acquired resistance to oestrogen deprivation: role for growth factor signalling kinases/oestrogen receptor cross-talk revealed in new MCF-7X model.

Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer

Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells

BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer

BRCA1 expression levels predict distant metastasis of sporadic breast cancers

Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth.

Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype

Cell proliferation in prostatic carcinoma: comparative analysis of Ki-67, MIB-1 and PCNA

Change in expression of ER, bcl-2 and MIB1 on primary tamoxifen and relation to response in ER positive breast cancer

Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment.

Corrigendum to “ONCOPOOL – A European database for 16,944 cases of breast cancer” [European Journal of Cancer 46 (2009) 56–71]

Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells.

Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications.

Development of strategies for the use of anti-growth factor treatments.

Differential Expression of Oestrogen Regulated Genes in Breast Cancer

Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study

ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer.

Effects of fulvestrant 250mg in premenopausal women with oestrogen receptor-positive primary breast cancer

Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes

Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.

Endocrine response and resistance in breast cancer: a role for the transcription factor Fos.

Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex).

Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy.

Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.

Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer

Estrogen deprivation in breast cancer. Clinical, experimental, and biological aspects

Evaluation of the current knowledge limitations in breast cancer research: a gap analysis

Expanding the therapeutic repertoire of epidermal growth factor receptor blockade: radiosensitization

Extreme growth factor signalling can promote oestrogen receptor-alpha loss: therapeutic implications in breast cancer

Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance.

Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1

Gamma linolenic acid with tamoxifen as primary therapy in breast cancer

Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.

Growth factor receptor interplay and resistance in cancer

Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer.

Growth factor signalling in endocrine and anti-growth factor resistant breast cancer.

Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance.

Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells

Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy

Immunocytochemical localization of fos protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy

Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro

Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells.

Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy.

Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells.

Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance.

Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor.

Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells

Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes

Investigating the mechanism of enhanced cytotoxicity of HPMA copolymer-Dox-AGM in breast cancer cells

Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer.

Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination

ONCOPOOL - a European database for 16,944 cases of breast cancer.

Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.

Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.

Overview of tyrosine kinase inhibitors in clinical breast cancer.

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.

Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer

Phosphorylation of ERα at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERα phosphorylation in breast cancer progression

Presence and possible significance of immunocytochemically demonstrable metallothionein over-expression in primary invasive ductal carcinoma of the breast.

Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer

Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets

Role of endoplasmic reticulum stress induction by the plant toxin, persin, in overcoming resistance to the apoptotic effects of tamoxifen in human breast cancer cells.

Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer

Steroid hormone receptors and their clinical significance in cancer.

TENB2, a proteoglycan identified in prostate cancer that is associated with disease progression and androgen independence

The Biology of Antihormone Failure in Breast Cancer ⬇️

The effects of gefitinib in tamoxifen-resistant and hormone-insensitive breast cancer: a phase II study.

The immunohistochemical expression of desmoplakin and its role in vivo in the progression and metastasis of breast cancer

Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen.

Understanding endocrine resistance: the critical need for sequential samples from clinical breast cancer and novel in vitro models

Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies.